n = 74 Range, % Range, % Range, % Hyperfiltration p-value
Median age, years, interquartile range 10.5 (6, 14.3) (6, 14.3) (6, 14.3) 0.74
Male 50 68% 68% 68% 0.79
Primary disorder malignancy 24 32% 32% 32% 1.00
Chemotherapy prior to referral for HSCT 37 50% 50% 50% 0.44
Sibling Donor 29 39% 39% 39% 0.12
Match 10/10 57 77% 77% 77% 0.15
Transplant Source 0.14
Peripheral blood
9
12%
12%
12%
Bone marrow
63
85%
85%
85%
Cord blood
2
3%
3%
3%
Myeloablative Allogeneic HSCT 45 61% 61% 61% 0.12
Total Body Irradiation 12 16% 16% 16% 0.41
Ex-vivo T cell depletion 7 9% 9% 9% 0.10
Outcomes
Stage 2+ Creatinine AKI in 1st year
44
70%
70%
70%
0.80
Dialysis ever
5
8%
8%
8%
0.63
Event free survival
55
87%
87%
87%
1.00
Abnormal creatinine eGFR >2 years post-SCT
12 of 39
31%
31%
31%
0.73
Outcomes assessed in 63 patients.